Decentralized Clinical Trials Involving Biologics: Unique Challenges

Decentralized clinical trial (DCT) modalities continue to transform the way we conduct clinical research. One surprising area: studies involving genetically modified biologics.

In this webinar, you’ll find out what FDA says about DCTs and biologics, and what this means in practice. Dr. Daniel Eisenman provides a biosafety perspective on these types of studies, explaining the unique risks and important considerations for ensuring safe, responsible trial conduct.

• Describe key ways biologics research differs from small molecule research
• Summarize what FDA guidance says about DCTs involving biologics
• Discuss ways to address the unique challenge of biologics in DCTs

• Presenter

Daniel Eisenman

PhD, RBP, SM(NRCM), CBSP

Executive Director, Biosafety Services, Advarra